|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:NantKwest
gptkb:Zymeworks
gptkb:LigoCyte_Pharmaceuticals
gptkb:Alder_BioPharmaceuticals
gptkb:Apexigen
gptkb:Tigenix
gptkb:Envoy_Therapeutics
gptkb:Shire_plc
gptkb:ArcherDX
gptkb:Hikma_Pharmaceuticals
gptkb:Talecris_Biotherapeutics
gptkb:MediGene_AG
gptkb:Shire_Pharmaceuticals
Kymab
TiGenix
Pioneer_Surgical_Technology
|
|
gptkbp:CEO
|
gptkb:Christophe_Weber
|
|
gptkbp:employees
|
50,000+
|
|
gptkbp:focus
|
Gastroenterology
Neuroscience
Oncology
Research and development
Vaccines
Biopharmaceuticals
Rare diseases
|
|
gptkbp:founded
|
1781
|
|
gptkbp:founder
|
gptkb:Chobei_Takeda_I
|
|
gptkbp:headquarters
|
gptkb:Osaka,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Takeda Pharmaceutical Company
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:partnerships
|
gptkb:Global_Health_Innovative_Technology_Fund
gptkb:World_Health_Organization
|
|
gptkbp:products
|
Vaccines
Oncology drugs
Rare disease treatments
|
|
gptkbp:revenue
|
$30 billion (2022)
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
4502
|
|
gptkbp:subsidiary
|
gptkb:Takeda_Pharmaceuticals_International_AG
gptkb:Takeda_Global_Research_&_Development_Center,_Inc.
Takeda Pharmaceuticals USA, Inc.
|
|
gptkbp:website
|
www.takeda.com
|